The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock
Abstract
BACKGROUND: Death from severe sepsis and septic shock is common, and researchers have explored whether antibodies to the endotoxins in some bacteria reduces mortality. OBJECTIVES: To estimate the effects of intravenous immunoglobulin (IVIG) in patients with bacterial sepsis or septic shock on mortality, bacteriological failure rates, and duration of stay in hospital. SEARCH STRATEGY: We searched the Cochrane Infectious Diseases Group specialized register up to November 2001; the Cochrane Controlled Trials Register, The Cochrane Library issue 4, 2001; MEDLINE 1966 to November 2001; and EMBASE 1988 to September 2001. We contacted investigators active in the field for unpublished data. SELECTION CRITERIA: Randomised trials comparing intravenous immunoglobulin (monoclonal or polyclonal) with placebo or no intervention, in patients with bacterial sepsis or septic shock. DATA COLLECTION AND ANALYSIS: Inclusion criteria, trial quality assessment, and data abstraction were done in duplicate. We conducted pre-specified subgroup analyses by type of immunoglobulin preparation. MAIN RESULTS: Twenty-seven out of 55 studies met our inclusion criteria. Pooled analysis of all types of IVIG preparations revealed a significant trend toward reduction of mortality (n= 8,856; RR=0.91; 95%CI 0.86-0.96). Overall mortality was reduced in patients who received polyclonal IVIG (n=492; RR=0.64; 95% CI 0.51 to 0.80). For the two high-quality trials on polyclonal IVIG, the RR for overall mortality was 0.30, but the confidence interval was wide (95% CI 0.09 to 0.99, n=91). Mortality was not reduced among patients who received monoclonal antibodies such as anti-endotoxins (n=2,826 in 5 good-quality studies; RR=0.97; 95% CI 0.88 to 1.07) or anti-cytokines (n=4,318; RR=0.93; 95% CI 0.86 to 1.01). A few studies measured secondary outcomes (deaths from sepsis or length of hospitalisation) but no differences in the intervention and control groups were identified except among those who received polyclonal IVIG, where sepsis-related mortality was significantly reduced (n=161; RR=0.35; 95% CI 0.18 to 0.69). REVIEWER'S CONCLUSIONS: Polyclonal IVIG significantly reduced mortality and and is a promising adjuvant in the treatment of sepsis and septic shock. However, all the trials were small and the totality of the evidence is insufficient to support a robust conclusion of benefit. Adjunctive therapy with monoclonal IVIGs remains experimental.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Early goal-directed therapy in the treatment of severe sepsis and septic shock
Rivers, E., Nguyen, B., Havstad, S., Ressler, J., Muzzin, A., Knoblich, B., Peterson, E., & Tomlanovich, M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010307 · Cited by 10,743
Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J.-L., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,995
Ziegler, E. J., Fisher, C. J., Sprung, C. L., Straube, R. C., Sadoff, J. C., Foulke, G. E., Wortel, C. H., Fink, M. P., Dellinger, R. P., Teng, N. N. H., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102143240701 · Cited by 1,611
Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein
Fisher, C. J., Agosti, J. M., Opal, S. M., Lowry, S. F., Balk, R. A., Sadoff, J. C., Abraham, E., Schein, R. M. H., & Benjamin, E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342603 · Cited by 1,241
Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a Mutant Escherichia coli
Ziegler, E. J., McCutchan, J. A., Fierer, J., Glauser, M. P., Sadoff, J. C., Douglas, H., & Braude, A. I. (1982) · New England Journal of Medicine · doi:10.1056/nejm198211113072001 · Cited by 1,046
Opal, S. M., Fisher, C. J., Dhainaut, J.-F. A., Vincent, J.-L., Brase, R., Lowry, S. F., Sadoff, J. C., Slotman, G. J., Levy, H., Balk, R. A., et al. (1997) · Critical Care Medicine · doi:10.1097/00003246-199707000-00010 · Cited by 865
Research works printed but not linked: 48
- Behre, 1995, Endotoxin concentrations and therapy with polyclonal IgM-enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: Pilot study and interim analysis of a randomized trial, Antiinfective Drugs and Chemotherapy., 13, 129
- Chen, 1996, Intravenous immunoglobulin in the treatment of full term and premature newborns with sepsis, Journal of the Formosan Medical Association: Taiwan Yi Zhi, 11, 839
- Simone, 1988, Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients, Critical Care Medicine, 16, 23, 10.1097/00003246-198801000-00005 · doi:10.1097/00003246-198801000-00005
- Dominioni, 1996, High-dose intravenous IgG for treatment of severe surgical infections, Digestive Surgery, 13, 430, 10.1159/000172479 · doi:10.1159/000172479
- Erdem, 1993, The use of IgM-enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants, The Turkish Journal of Pediatrics, 35, 277
- Haque, 1988, IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis, American Journal of Diseases of Childhood, 142, 1293
- Lindquist, 1981, Pepsin-treated human gamma globulin in bacterial infections. A randomized study in patients with septicemia and pneumonia, Vox Sanguinis, 40, 329, 10.1111/j.1423-0410.1981.tb00717.x · doi:10.1111/j.1423-0410.1981.tb00717.x
- Mancilla-Ramírez, 1992, Intravenous immunoglobulin in the treatment of neonatal septicemia, Boletín Médico del Hospital Infantil de México, 49, 4
- Masaoka, 2000, The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections, Japanese Journal of Chemotherapy, 48, 199
- Samatha, 1997, Role of IgM-enriched intravenous immunoglobulin as an adjuvant to antibiotics in neonatal sepsis, Karnataka Pediatric Journal, 11, 1
- Yakut, 1998, Effects of immunoglobulin G on surgical sepsis and septic shock, Bulletin of Gulhane Military Medical Academy, 40, 76
- Aitchison, 1985, Anti-endotoxin in the treatment of surgical septic shock. Results of a randomized double-blind trial., South African Medical Journal, 68, 787
- Bojic, 1998, The significance of immunoglobulins in the treatment of patients with sepsis and septic shock, Vojnosanitetski Pregled. Military-medical and Pharmaceutical Review, 55 (2 Suppl), 75
- Fischer, 1983, Functional antibacterial activity of a human intravenous immunoglobulin preparation: in vitro and in vivo studies, Vox Sanguinis, 44, 296, 10.1111/j.1423-0410.1983.tb04485.x · doi:10.1111/j.1423-0410.1983.tb04485.x
- Freeman, 1999, The role of inflammation in sepsis and septic shock: a meta-analysis of both clinical and pre-clinical trials of anti-inflammatory therapies, 965
- Gökalp, 1994, Intravenous immunoglobulin in the treatment of Salmonella typhimurium infections in preterm neonates, Clinical Pediatrics, 33, 349, 10.1177/000992289403300607 · doi:10.1177/000992289403300607
- Gunes, 2006, Exchange transfusion or intravenous immunoglobulin therapy as an adjunct to antibiotics for neonatal sepsis in developing countries: a pilot study, Annals of Tropical Paediatrics, 26, 39, 10.1179/146532806X90592 · doi:10.1179/146532806x90592
- Haque, 1995, Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis, Clinical and Experimental Immunology, 101, 328, 10.1111/j.1365-2249.1995.tb08359.x · doi:10.1111/j.1365-2249.1995.tb08359.x
- Homan, 1990, Safety of intravenous immunoglobulin in neonates at risk for sepsis, American Journal of Perinatology, 7, 267, 10.1055/s-2007-999510 · doi:10.1055/s-2007-999510
- Jaspers, 1987, Antibody to lipid A in the treatment of septic shock, Infection, 15 Suppl 2, 89, 10.1007/BF01644200 · doi:10.1007/bf01644200
- Jesdinsky, 1987, Cooperative group of additional immunoglobulin therapy in severe bacterial infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis, Klinische Wochenschrift, 65, 1132, 10.1007/BF01734833 · doi:10.1007/bf01734833
- Jones, 1995, Prophylactic anti-lipopolysaccharide freeze-dried plasma in major burns: a double blind controlled trial, Burns, 21, 267, 10.1016/0305-4179(94)00004-H · doi:10.1016/0305-4179(94)00004-h
- Kett, 1994, An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody, Critical Care Medicine, 22, 1227, 10.1097/00003246-199408000-00005 · doi:10.1097/00003246-199408000-00005
- Kornelisse, 1997, Meningococcal septic shock in children: clinical and laboratory features, outcome and development of a prognostic score, Clinical Infectious Diseases, 25, 640, 10.1086/513759 · doi:10.1086/513759
- Marenovic, 1998, High doses of immunoglobulins decrease mortality rate of surgical patients with severe intraabdominal infections and sepsis, Vojnosanitetski Pregled. Military-medical and Pharmaceutical Review, 55 (2 Suppl), 71
- Okimoto, 1985, Clinical studies on the effectiveness of SM-4300, a new non-modified gamma globulin preparation suitable for intravenous use, in refractory infections, The Japanese Journal of Antibiotics, 38, 2515
- Panko, 1976, Use of staphylococcal plasma and antistaphylococcal immunoglobulin in treatment of staphylococcal sepsis, Khirurgiia, 9, 95
- Pilz, 1997, Comparison of early IgM-enriched immunoglobulin vs. polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis, Chest, 111, 419, 10.1378/chest.111.2.419 · doi:10.1378/chest.111.2.419
- Schedel, 1996, [Therapy of gram-negative septicotoxic diseases with pentaglobin - immunoglobulin with increased IgM content: a prospective randomized clinical study], Anesteziologiia i Reanimatologiia, 199, 4
- Sidiropolous, 1981, "Immunoglobulin substitution in the treatment of neonatal septicemia". Schweizerische Medizinische Wochenschrift, Schweizerische Medizinische Wochenschrift, 111, 1649
- Tomii, 1985, Clinical study of SM-4300 in the field of medicine, The Japanese Journal of Antibiotics, 38, 2503
- Ueda, 1985, A clinical trial of SM-4300 against severe infections in surgery, The Japanese Journal of Antibiotics, 38, 2647
- Wang, 2006, Treatment of septic thrombocytopenia with immunoglobulin, Chinese Journal of Emergency Medicine, 15, 905
- Yildizidas, 2005, Does polyclonal intravenous immunoglobulin reduce mortality in septic children in pediatric intensive care unit?, Cocuk Sagligi Ve Hastaliklari Dergisi, 48, 136
- 2008, The INIS Study. International Neonatal Immunotherapy Study: Non-specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo-controlled, multicentre randomised trial, BMC Pregnancy and Childbirth, 8, 1
- Alejandria, 2000, Epidemiology and predictors of mortality from sepsis in medical patients at UP-PGH, Philippine Journal of Microbiology and Infectious Diseases, 29, 23
- Dahlberg, 1997, Endotoxins and sepsis, 45
- Fisher Jr, 1997, Interpreting large-scale clinical sepsis trials: a retrospective view, 627
- Norrby-Teglund, 2003, Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections, Scandinavian Journal of Infectious Diseases, 35, 683, 10.1080/00365540310015944 · doi:10.1080/00365540310015944
- Nydegger, 1997, Sepsis and polyspecific intravenous immunoglobulins, Journal of Clinical Apheresis, 12, 93, 10.1002/(SICI)1098-1101(1997)12:2<93::AID-JCA7>3.0.CO;2-4 · doi:10.1002/(sici)1098-1101(1997)12:2<93::aid-jca7>3.0.co;2-4
- Rangel-Frausto, 1995, The natural history of the systemic inflammatory response syndrome (SIRS), JAMA, 274, 968, 10.1001/jama.1995.03530020045022 · doi:10.1001/jama.1995.03530020045022
- The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008
- Taguiang-Abu, 2008, Clinical determinants of outcome of severe sepsis among adult patients at the Philippine General Hospital Intensive Care Units, Philippine Journal of Internal Medicine, 46, 103
- Villa, 1995, Sepsis profile among patients in a tertiary care hospital, St Luke's Medical Journal, 2, 45
- Werdan K Pilz G the SBITs Study Group Polyvalent immune globulins [Abstract 18] Shock 1997 1918 · doi:10.1097/00024382-199703001-00020
- Werdan, 2001, Pathophysiology of septic shock and multiorgan dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins, Therapeutic Apheresis, 5, 115, 10.1046/j.1526-0968.2001.005002115.x · doi:10.1046/j.1526-0968.2001.005002115.x
- Wortel, 1993, Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective randomized clinical trial (Letter to the Editor), Critical Care Medicine, 21, 163, 10.1097/00003246-199301000-00042 · doi:10.1097/00003246-199301000-00042
- Alejandria, 2002, Intravenous immunoglobulin for treating sepsis and septic shock, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD001090
Cited by
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
“’’ [68]”
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup*, Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,290
Metadata
- Authors
- Alejandria, M. M., Lansang, M. A. D., Dans, L. F., & Mantaring III, J. B.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2002-01-21
- Issue
- 1
- Pages
- CD001090-CD001090
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W29480699
- Cited by
- 313
- References
- 74
- Type
- reference entry
- Language
- en
- Update notices
- new_version (2013-09-16)
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. https://app.cochat.ai/papers/10.1002/14651858.cd001090
- The paper
- Alejandria, M. M., Lansang, M. A. D., Dans, L. F., & Mantaring III, J. B. (2002). Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd001090
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.